SOURCE-LINKED STUDY SUMMARY
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
Abstract summarizedQuality not appraised
- What was studied
- A blinded, randomized phase 1 trial evaluated eloralintide's safety, tolerability, drug exposure and effects in adults with overweight or obesity.
- Who / model studied
- 100 participants at three US centres averaged 44 years of age and a body mass index of 32.6; 29% were female.
- Studied dose & schedule
- Weekly subcutaneous eloralintide or placebo for 12 weeks, without dose escalation within participants. Five dose cohorts were studied; the abstract identifies a 6 mg cohort but does not list all doses.
- What the study found
- Weight decreased 2.6–11.3% across eloralintide groups; the abstract provides no placebo-adjusted weight estimate. Events included decreased appetite, headache, fatigue and gastrointestinal symptoms, mostly mild. No deaths occurred; one serious event in the 6 mg cohort was considered unrelated.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/dom.70439